Real-world safety of tirofiban: a disproportionality analysis using data from FAERS and WHO-VigiAccess.

ABSTRACT:

Objective

This study aimed to detect tirofiban-related adverse event (AE) signals using the FAERS and WHO-VigiAccess databases to support safer clinical use.

Methods

All tirofiban-related AE reports were retrieved from FAERS (2004Q1 to 2024Q4) and WHO-VigiAccess (Retrieval date 2024.12.15). Disproportionality analyses were performed using ROR (Reporting Odds Ratio), PRR (Proportional Reporting Ratio), BCPNN (Bayesian Confidence Propagation Neural Network), and MGPS (Multi-item Gamma Poisson Shrinker) to detect potential drug-AE associations. Time - to - onset was assessed with Weibull distribution and Kaplan-Meier methods. Sensitivity analyses were performed according to reporter type, age group, and sex to assess the robustness of the findings.

Results

A total of 2,4

SUBMITTER: Li J 

PROVIDER: S-EPMC12738861 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature